Akebia Therapeutics, Inc. (AKBA) is a publicly traded Healthcare sector company. As of May 21, 2026, AKBA trades at $1.01 with a market cap of $270.94M and a P/E ratio of -12.30. AKBA moved +12.28% today. Year to date, AKBA is -33.11%; over the trailing twelve months it is -65.41%. Its 52-week range spans $0.88 to $4.08. Analyst consensus is strong buy with an average price target of $4.67. Rallies surfaces AKBA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Akebia Q1 Vafseo Sales Hit $15.8M with 60% Patient Growth, FSGS Trial Advances: Vafseo net product revenues rose to $15.8 million in Q1 2026, with prescribers up 28% to 1,025 and patients up 60% quarter-over-quarter. Akebia’s pipeline progressed with Phase 2 praliciguat enrollment in FSGS and a planned Phase 2 AKB-097 basket trial in IgA nephropathy and lupus nephritis.
| Metric | Value |
|---|---|
| Price | $1.01 |
| Market Cap | $270.94M |
| P/E Ratio | -12.30 |
| EPS | $-0.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.08 |
| 52-Week Low | $0.88 |
| Volume | 302 |
| Avg Volume | 0 |
| Revenue (TTM) | $232.40M |
| Net Income | $-20.51M |
| Gross Margin | 81.01% |
3 analysts cover AKBA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.67.